High-performance result and above consensus outlook drive BlueScope higher

Published 20-FEB-2017 09:16 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Global steel producer, BlueScope Steel (ASX: BSL) delivered a strong first half net profit of $360 million for the first half of fiscal 2017, representing an increase of circa 200% compared with the previous corresponding period.

However, the focus is likely to be on the strong second half guidance which points to full-year earnings before interest and tax (EBIT) of $1.11 billion. As a point of comparison, analysts at Citi were forecasting full-year EBIT of US$1.03 billion.

Focusing on the first half result, it was ahead of Macquarie’s estimates of $348.6 million, and the capital management initiatives announced by management should be well received by shareholders.

Citing the group’s strong cash flow generation ($900 million in calendar year 2016), BlueScope’s chairman, John Bevan said, “In light of the company’s sound cash flow position the board has approved the payment of a fully franked dividend of 4 cents per share and approved and on market share buyback of up to $150 million”.

From an operational perspective, it was a strong result across the board, but focusing on the key growth driver, it was the performance of its North Star steel business that was a standout. The group moved to full ownership of the North Star operations in October 2015 and has continued to achieve improvements in margins.

The benefits of these developments are now hitting the bottom line with the business recording a 178% year-on-year rise in underlying EBITDA (US$180.2 million) in the first half of fiscal 2017. Given the upbeat confidence surrounding the US economy generally, the North Star business is likely to be seen as a continuing source of robust growth.

BlueScope’s coated and painted products business was supported by strong demand in Australia as EBIT increased by 70%. Management intends to focus on growing this area of its business in Asia as it is highly leveraged to the rapid rise in middle-class wealth.

The BlueScope Buildings division delivered underlying EBIT of $49.5 million, representing year-on-year growth of 45%, largely driven by improvements in the North American business.

Having delivered a slightly better than expected profit, initiated an earnings per share accretive capital management strategy and provided full-year guidance ahead of analyst’s expectations BlueScope’s share price could receive support when markets open on Monday.

Prior to the release of this result, Citi had a price target of $13.34 on the stock, implying upside of nearly 10% to Friday’s closing price of $12.19. However, this performance may have Citi and a number of analysts revising their numbers.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free